Skip to main content

Emtricitabine Disease Interactions

There are 3 disease interactions with emtricitabine.

Major

NRTIs (applies to emtricitabine) hepatitis B

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis

Severe acute exacerbations of HBV have been reported in HIV-1/HBV-coinfected patients who have discontinued products containing emtricitabine, lamivudine, and/or tenofovir disoproxil fumarate (DF) and may occur with discontinuation of tenofovir alafenamide-containing products. It is recommended that all patients with HIV-1 infection be tested for the presence of HBV before or when initiating products containing emtricitabine, lamivudine, tenofovir DF, or tenofovir alafenamide. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in HIV-1/HBV-coinfected patients who discontinue products (including fixed-dose combination products) that contain emtricitabine, lamivudine, tenofovir DF, or tenofovir alafenamide. If appropriate, initiation or resumption of antihepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis since posttreatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.

Switch to professional interaction data

Moderate

Emtricitabine (applies to emtricitabine) hemodialysis

Moderate Potential Hazard, Moderate plausibility.

Emtricitabine is removed by hemodialysis. When started within 1.5 hours of emtricitabine dosing, about 30% of the dose was removed over a 3-hour hemodialysis session (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). If dosing on day of hemodialysis, emtricitabine should be administered after hemodialysis.

Switch to professional interaction data

Moderate

Emtricitabine (applies to emtricitabine) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Emtricitabine is primarily eliminated by the kidney. Dosage adjustment of emtricitabine is recommended for patients with CrCl below 50 mL/min or in patients with ESRD requiring dialysis, in accordance with the manufacturer product information. Clinical response to treatment and renal function should be closely monitored.

Switch to professional interaction data

Emtricitabine drug interactions

There are 49 drug interactions with emtricitabine.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer